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Background: Drug resistance is one of the main reasons of anti-malarial treatment failures and impedes malaria
containment strategies. As single nucleotide polymorphisms (SNPs) have been found to correlate with anti-malarial
drug resistance, the surveillance strategy includes continuous monitoring of known molecular markers and detection
of new mutation patterns. With the introduction of artemisinin-based combination therapy, selection of specific
patterns has been observed worldwide.
Methods: From March to June 2013, whole blood was collected on filter paper from microscopically malaria positive
patients in Jimma zone (District), southwestern Ethiopia. Plasmodium falciparum, Plasmodium vivax and mixed
infections were included. SNPs were investigated by conventional or real-time PCR, restriction fragment length pattern
analysis or sequencing. Results were compared to molecular patterns from Ethiopian isolates in 2004, 2006 and 2008/9.
Results: Plasmodium falciparum, P. vivax, and mixed infections were molecularly confirmed in 177, 80, and 14 samples,
respectively. In P. falciparum, mutations in the pfcrt, pfmdr 1and pfATP 6 (SERCA) gene were investigated. Whereas the
mutation in the pfcrt gene at codon 76 K was still found in 95.6 % of all samples, the pfmdr 1 86 T mutation fell to
1.2 % (2/163) in 2013 compared to 9 % in 2008/9 and 86 % in 2006 (P <0.001). The pfmdr 1 184 F mutation dominated
with 100.0 % (172/172) in 2013. Sequencing of the recently reported PF3D7_1343700 kelch propeller domain showed
no mutation at codon 476. First sequencing data of the pvmdr 1 gene from Jimma region revealed a prevalence of the
mutations 976 F and 1076 L in 72.7 % (16/23) and 100.0 % (19/19) of the isolates, respectively.
Conclusion: Since the introduction of artemether-lumefantrine (AL) in Jimma, Ethiopia, in 2006, the prevalence of
certain SNPs associated with AL use has increased. Markers for chloroquine resistance in P. vivax were highly frequent.
Continuous molecular and clinical surveillance are of paramount importance.Background
The rise of drug-resistant parasites threatens to hamper
malaria containment strategies. After the introduction of
artemisinin-based combination therapy (ACT) in Jimma
zone in 2006 [1], a certain shift in the distribution of
wild types and mutations of defined single nucleotide
polymorphisms (SNPs), associated with anti-malarial
drug resistance, was expected.
The Plasmodium falciparum chloroquine resistance
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unless otherwise stated.transmembrane protein to be found in the digestive
vacuole of the parasite and has primarily been associated
with resistances to chloroquine (CQ). However, it also
seems to influence artemisinin, quinine and amodia-
quine susceptibility [2–4]. The P. falciparum multi-drug
resistance protein 1 (pfmdr 1) gene, located on chromo-
some 5, encodes a P-glycoprotein homologue 1 [5, 6].
Point mutations in codon 86 and 184 seem to be in-
volved in artemether-lumefantrine (AL) resistance in
some [7–10] but not all studies [11]. Concerning CQ,
the PfMDR 1 protein is believed to add a modulatory ef-
fect to resistance mechanisms without conferring actual
resistance [12]. An increased copy number has been
linked to affect mainly mefloquine, but also artesunate,al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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trine susceptibility [13–15]. Increased copy numbers of
this gene however, do appear to play a minor role on the
African continent [8, 9, 16].
The P. falciparum SERCA-type ATPase 6, encoded by
the pfATP 6 gene, was suggested to be the cytosolic tar-
get structure of artemisinins [17–19]. A variety of poly-
morphisms located in the pfATP 6 gene have been
reported [20–23]. However, their actual importance con-
cerning artimisinin resistance remains unclear. Recently,
mutations in the K13-propeller gene encoding the
PF_1343700 kelch propeller domain have been proposed
to be determinants for artemisinin resistance [24]. Yet
its actual function within the parasite organism is un-
known and can only be assumed, as homologous pro-
teins in other organism can be found participating in a
wide variety of pathways [24–26].
The P. vivax multi-drug resistance protein1, encoded
by the pvmdr 1 gene, is the pfmdr 1 orthologue in P.
vivax and is presumed to be connected to changes of
CQ, amodiaquine and sulfadoxine-pyrimethamine treat-
ment response. Specifically mutations in codon 976 and
1076 seem to be responsible for the aforementioned as-
sociations [27–29].
In this present study, the prevalence of these molecu-
lar markers in southwestern Ethiopia collected in 2013
was compared to earlier published and partially unpub-
lished data from 2004, 2006 and 2009 from this region
[30–32].
Methods
Study site and patient material
Sample collection took place from March until June
2013 in five different health centres in Goma province
around Jimma town, approximately 355 km southwest of
the Ethiopian capital Addis Ababa. Malaria transmission
is seasonal with minor transmission from April to June
and major transmission from September to December.
The study was implemented in the routine diagnostic
settings. When malaria was clinically suspected, micro-
scopic investigations of blood slides were performed.
Slides were stained with Giemsa and independently read
by two experienced microscopists. Only microscopically
malaria-positive patients were considered for inclusion
in the study. Plasmodium falciparum and P. vivax single
infections as well as mixed infections were included in
the study. Pregnant women and children under the age
of one year were excluded. Ethical clearance was granted
by the Ethical Committee of the Universitiy of Jimma,
Ethiopia, as well as of the University of Munich,
Germany. A signed and dated informed consent form
was obtained from each patient or parent/guardian as
applicable. Blood samples for molecular investigations
were derived from fingerprick samples applied on filterpaper (Standard-Whatman Cellulose Chromatography
paper 3MM, GE Healthcare, Fairfield, CT, USA) after re-
cruitment. Filter papers were air-dried, individually
packed in sterile DNA free zipper bags and stored in
Jimma at ambient temperature. After arrival in Munich,
samples were stored frozen at −20 °C.
DNA extraction and amplification
DNA was extracted from filter paper using the Chelex
method as described earlier [31, 33]. For parasite specifi-
cation, a nested conventional polymerase chain reaction
(PCR) was used [34]. In order to survey the pfcrt 76 K
mutation, a nested conventional PCR followed by en-
zyme digestion with ApoI was performed as described
previously [2, 35]. The specific restriction fragment
length pattern (RFLP) analysis enables to discriminate
between mutation and wild type. The validity of the
assay was confirmed by sequencing 10 % of the samples
and comparing the obtained results with the RFLP
result.
To analyse pfmdr 1 mutations at codons 86 and 184,
the real-time PCR described by Purfield et al. was estab-
lished [36]. Again, the validity of the method was con-
firmed by sequencing of 10 % of the samples. Pfmdr 1
copy numbers were investigated as previously described
in more detail [14]. The method was thereby adapted for
a Biorad real-time PCR cycler.
Gel electrophoresis was performed with DNA GelRed™
stained 1.25-2 % agarose gels. For RFLP discrimination,
high-resolution agarose (Roth®) was used.
Sequencing was performed using Big Dye Terminator
3.1 and DyeEx® 2.0 Spin Kit as described earlier [31].
Amplified fragments from pfATP 6, pvmdr 1 and the
newly described K13-propeller gene were sequenced using
the same primer sequences as used for PCR amplification.
For all primer sequences refer to Additional file 1. Gen-
omic sequences were analysed by the sequence alignment
editors Bioedit and DNASIS MAX (version 3.0). Reference
sequences were obtained from the National Center for
Biotechnology Information (NCBI). Sequence similarity
was investigated via Basic Local Alignment Search Tool
(BLAST) [37]. (Reference sequences: pfmdr 1 3D7
AL844501.1, pfcrt XM_001348968.1, pfATP 6 AB1210
59.1, K13 propeller XM_001350122.1, pvmdr 1 EU333
975.1,).
Results
Sample collection and species differentiation
Altogether 338 finger prick samples of microscopically
positive malaria patients were collected. Seventeen (5.0 %)
samples originated from Choche Health Centre, 24 (7.1 %)
from Limu Shay Health Centre, 154 (45.6 %) from Didisa
Health Centre, three (0.9 %) from Jimma Health Centre,
and 140 (41.4 %) from Shanan Gibe Hospital. Plasmodium
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in 197 (61.2 %) and 98 (30.4 %) samples, respectively. A
total of 27 (8.4 %) samples were classified as mixed infec-
tions with both species. For 16 samples, microscopic data
were missing.
Molecular species differentiation by nested PCR con-
firmed 177 samples of P. falciparum, 80 samples of P.
vivax and 14 mixed samples. A 67 of 338 (19.8 %) sam-
ples remained molecularly malaria-negative. Repetition
and increase in DNA template resulted in the same re-
sult. Prevalence of P. falciparum and P. vivax mono-
infections in these 271 positive samples were 65.3 % and
29.5 %, respectively.Molecular patterns in Plasmodium falciparum
In P. falciparum the following codons were assessed,
mixed infections were included in the analysis: pfcrt 76,
pfmdr1 86 and 184, pfATP 6 codons 263–431 and the re-
cently published K13-propeller domain with codon 476.
The amplification and enzyme digestion of the pfcrt
amplicon was successful for 159 samples. Within these,
152 (95.6 %) samples showed the mutation at codon
76 T, whereas only seven showed wild type (76 K) char-
acteristics (Table 1). No mixed infections (wild type and
mutation in one sample) could be detected. Sequencing
10 % of the samples revealed that both, the CVIET and
CVMNT haplotype are present in 50 % of cases in co-
dons 72–76. Interestingly, in 2009 the CVIET haplotype
could be found in all cases.
Concerning the pfmdr 1 gene, only two samples were
identified as pfmdr 1 86Y mutants. The prevalence of
the 86 N dominated with 98.8 % (n = 161). The pfmdr 1Table 1 Prevalence of wild type and mutation in different
genes in P. falciparum and P. vivax in Jimma, Ethiopia 2013
Gene Codon Wild type Mutation
N (%) N (%)
Plasmodium falciparum
K13-propeller M476I 25/25 (100.0) 0/25 (0)
N531I 24/25 (96.0) 1/25 (4.0)
pfATP 6 L402V 32/32 (100.0) 0/32 (0.0)
E431K 39/48 (81.2) 9/48 (18.8)
pfmdr 1 N86Y 161/163 (98.8) 2/163 (1.2)
Y184F 0/171 (0.0) 171/171 (100.0)
pfcrt K76T 7/159 (4.4) 152/159 (95.6)
pfcrt + pfmdr1 K76T, N86Y 5/159 (3.1) 1/159 (0.6)
Plasmodium vivax
pvmdr Y976F 6/22 (22.3) 16/22 (72.7)
F1076L 0/19 (0) 19/19 (100.0)
1Showing both wild type or both mutationY184F haplotype was found in all 171 amplified samples
(Table 1). No mixed infections were observed. Pfmdr
copy numbers were only investigated in 2009, all sam-
ples showed only one copy of the gene.
Sequencing of the pfATP 6 gene was performed from
50 randomly chosen samples, the K13- propeller region
was sequenced from 25 randomly selected samples. The
pfATP 6 431 K mutation showed a prevalence of 18.8 %
(9/48). One sample failed to amplify properly, another
sample was not distinguishable by sequencing results
(Table 1). Given that the sequences often were too short
to allow full judgement, no other mutations could be
confidently proven.
As the K13-propeller gene is uncommonly long for the
sequencing method used, only sequences from codon
343 to codon 693 could reliably be assessed. No muta-
tions including M476I as described in Ariey et al. [24]
were detected. However, one mutation at codon 531
(N531I) was identified that had not been described earl-
ier (Table 1).
There was no significant difference in the distribution
of molecular patterns between the different health
centres.
Molecular patterns in Plasmodium vivax
Sequencing results of the pvmdr1 gene have not been re-
ported before from this region.
From 24 out of 25 randomly chosen samples, a partial
pvmdr1 sequence could be successfully amplified and se-
quenced. The homology with the reference strain
(EU333975.1) was 100 % for the wild type. The sequence
proved to be highly conserved on a global level. There was
no difference in similarity between regionally closer iso-
lates compared to isolates from other continents apart
from the formerly described mutations at codon 976 and
1076. Prevalence of the Y976F mutation was 72.7 %, all
readable samples showed the F1076L mutation. Two and
five samples were indistinguishable for codon 976 and
1076, respectively. No other mutations were found in
these sequences spanning from codon 938 to 1086. There
was no significant difference in the distribution of molecu-
lar patterns between the different health centres. Two ex-
emplary sequences are published at GenBank [38].
Mutations over time
Mutations in the following P. falciparum genes were in-
vestigated over time: pfcrt, pfmdr, and pfATP 6 (Fig. 1).
The sample size was 98 and 251 in 2006 and 2009, re-
spectively. Mutation analysis of the pfcrt and pfmdr 1
gene was performed for all samples. Confirmative se-
quencing was conducted for 10 % of these samples in
2009. On average, 15 % and 10 % of all samples were
successfully sequenced at the pfATP 6 gene in 2006 and
2009, respectively.
Fig. 1 Prevalence of investigated mutations over time. Alterations of molecular markers with regard to the introduction of ACT in Jimma zone in 2006.
No significant change in the pfcrt gene sequence was observed. The SERCA 431 K mutation dropped from 58.3 % in 2006 to 18.8 % in 2013 but the
sample size was very low. Changes in the pfmdr 1 gene were remarkable. In 2006 the mutation at codon 86Y was dominant with 80.6 %. Mixed
infections were taken together with wild type samples. The wild type alone was only detectable in 14.3 %. In 2009 and 2013, only 9.2 % and 1.2 %
showed the mutation 86Y, respectively. The prevalence of pfmdr 1 84 F was high in 2009 and remained dominant. Data from 2004 are taken from
reference 30
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served. Prevalence of the wild type remained negligible
(4.4 %). However, changes in the pfmdr 1 gene were re-
markable. Until 2006, the mutation at codon 86Y was
dominant: 80.6 % (79/98) of the samples showed the mu-
tation, only 14.3 % presented the wild type, the rest were
mixed clone infections presenting both haplotypes [31]. In
2009, the distribution had changed dramatically. Only
9.2 % showed the mutation 86Y and 228 of the 251 sam-
ples (90.8 %) presented the wild type 86 N [32]. In 2013,
the prevalence of 86Y dropped to as low as 1.2 %. Pfmdr 1
184 F was first investigated in 2009, the prevalence was
98 %, increasing to 100 % in 2013. The pfATP 6 431 K mu-
tation dropped from 58.3 % (7/12) in 2006 to 18.8 % (9/48) in 2013 but the sample size was very low. Other muta-
tions described in this short sequence were not detectable.
Discussion
In this study, molecular resistance patterns in Ethiopian P.
falciparum and P. vivax isolates were investigated. Pfcrt
76 T, associated mainly with CQ resistance, could be
found almost as frequently as before introduction of ACT.
Either continuous CQ use remains common in Jimma re-
gion, or the pfcrt wild type provides no fitness advantage
under AL treatment. As the wild type 76 K re-emerged
under ACT and in absence of CQ in some countries [39],
continuous CQ treatment in Jimma region should be at
least suspected. CQ is not recommended nor released in
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available on the free market and recommended for P.
vivax treatment.
As shown above, microscopic diagnosis was not always
reliable; performance was similar in all health centres.
Only in 203 (60.1 %) of all samples, the microscopy re-
sult matched the PCR result. A total of 16 samples
microscopically diagnosed as vivax malaria could be
proven to be P. falciparum infections by PCR. Overall,
19.8 % microscopically positive samples were negative by
PCR, 21 were microscopically categorized as vivax mal-
aria and treated accordingly. Therefore, P. falciparum
parasites still have opportunities to get in contact with
CQ. Also, self-treatment of the rural population in less
severe cases seems to be still very common as CQ is
cheap and easily available. The prevalence of P. vivax in
Jimma region is between 30-70 % [40]. The performance
data are consistent with a recent study from Ethiopia
assessing malaria diagnostic capacities in Ethiopian
health centres [41]. A recent study from Mozambique
showed a very similar changing pattern. The pfmdr 1 al-
lele N86 increased from 19.5 % in 2003–2005 to 73.2 %
in 2010–2012 after introduction of AL [42]. Interest-
ingly, a recent study from southeast Ethiopia (Omo
Nada, Bala Wajo, Arba Minch and Harar) showed differ-
ent results [43]. The authors declared a consequent ab-
sence of CQ use in this area. Prevalence of 76 T was
13.5 % (23/170) in the South and 32 % (8/25) in the East.
Overall, the C72S mutation was observed only in 3.6 %.
The authors further stated that the CQ-sensitive
CVMNK haplotype was found in 95.9 %, the mutant
haplotype SVMNT in 4.1 % and CVIET was absent at
codons 72–76. Sequencing of the mutant samples from
Jimma showed in 100 % the CVIET haplotype in 2009
and 50 % CVIET / 50 % CVMNT in 2013, in accordance
with other studies from Africa [32]. The C72S mutation
was absent as well as the sensitive CVMNK haplotype.
However, a shift to CVMNT might be a possible inter-
pretation. These regional differences are highly interest-
ing and warrent further investigation.
The Pfmdr 1 wild type 86 N was frequently detected in
areas where AL is used. A selection for or re-introduction
of the wild type is discussed for artemether as well as
lumefantrine and might be the explanation for this drastic
change [7–10]. Since the introduction of AL in Jimma
zone in 2006, the prevalence of the wild type remarkably
increased (P <0.001, data from 2006 compared to 2013 by
Wilcoxon rank-sum test; Fig. 1). Comparing the pfmdr1
184 haplotype with data from 2009, the prevalence of the
mutation remained stable at above 98 %. These findings
support the theory that the pfmdr1 184 F is selected under
drug pressure, especially under AL treatment [9]. Unfortu-
nately, no earlier data exists for pfmdr 1 Y184F from this
area. A recent study from southeast Ethiopia reported aprevalence of 9 % for N86 [40]. This is similar to the data
observed in this study. The prevalence of Y184F was 5 %
only compared to 100 % in this study. Different selection
mechanisms might be responsible. The diagnostic tool
used in this study consisted of a real-time PCR with se-
lective probes, sequencing was only performed in 10 % of
the samples but the latter consistently confirmed the re-
sults of the PCR.
In 2009, all samples from Jimma showed only one pfmdr
copy. In the above-mentioned study from southeast
Ethiopia, all samples presented also with only one copy
[43]. This is in accordance with other studies from Africa
[8, 9, 16].
The prevalence of the E431K mutation in the pfATP 6
gene dropped from 58.3 % in 2006 [31] to 18.8 % in
2013. Recently, E431K together with A623E has been de-
scribed to reduce artimisinin susceptibility [20]. The
A623E mutation was extremely rare with 1/24 (4.2 %) in
2006 and 0/33 (0 %) in 2009. No samples with both mu-
tations could be detected. The mutation was not
assessed in 2013 but the decline of the E431K mutation
contradicts selection of it under artemisinin pressure.
The new potential candidate referring resistance to
artemisinins, the K13 propeller gene, showed no muta-
tions at codon 476. This mutation has been described by
Ariey et al. in highly resistant samples from Cambodia
[24]. A new mutation at codon N531I was found in only
one isolate. Clinical effectiveness of AL was still 95 % in
2009. Clearance rates showed no significant prolonga-
tion, no resistance could be suspected then. More recent
clinical data from this area were not available [40].
Sequencing of the pvmdr 1 gene revealed a high preva-
lence of the Y976F and F1076L mutations. This corre-
lates well with the long lasting CQ use in this area.
Treatment failures were reported in recent P. vivax
studies [43–46]. Comparison of the Ethiopian pvmdr 1
sequences to sequences from Brazil (AY571984.1),
Cambodia (JQ925836.1), India (KC818412.1), Korea
(GU476519.1, GU244390.1) Madagascar (EU683815.1)
and Thailand (KC121338.1) showed highly conserved
features without systematic geographical clustering.Conclusion
The prevalence of SNPs associated with drug resistance
has been influenced since the introduction of AL treat-
ment in Ethiopia in 2006 (P <0.001). The wild type of
pfmdr codon 86 seems to possess a selection advantage.
No significant change was observed for the pfcrt codon
76. First sequencing data of the K13 propeller region re-
vealed no mutations as described in Asia. Mutations as-
sociated with CQ resistance in pvmdr 1 were highly
prevalent. Continuous molecular and clinical surveil-
lance are of paramount importance.
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